Clinical Trials

Phase 2 Not yet recruiting

Nasopharyngeal Carcinoma

NCT07381075 2026-02-02

A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

120 enrolled

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT05807880 2026-01-23

ALTER-HN005

59 enrolled

Nasopharyngeal Neoplasms

NCT05001971 2026-01-15

Anlotinib Plus Penpulimab as Second-line Treatment for Patients With Small Cell Lung Cancer After Failure of Platinum-based Chemotherapy

Phase 2 Completed

65 enrolled

Small Cell Lung Carcinoma

NCT05576480 2025-08-28

SPARC

55 enrolled

Phase 2 Not yet recruiting

Rectal Neoplasms

NCT06516978 2024-07-24

A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL

528 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT05229003 2024-07-03

Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC

44 enrolled

Colorectal Neoplasms

NCT05493995 2024-05-09

PAAG

Phase 2 Completed

66 enrolled

Pancreatic Neoplasms

NCT06341530 2024-04-02

Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer

33 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05028504 2023-12-27

ALTER-GO-020

86 enrolled

Gynecological Cancer

NCT05494060 2023-11-07

EXPLORING

80 enrolled

Carcinoma, Digestive System Diseases, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Stomach Neoplasms

NCT06114225 2023-11-02

PROMIS

43 enrolled

Sarcoma

Osteosarcoma

NCT06081673 2023-10-13

Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC

72 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06051851 2023-09-25

RCT-PAAG

177 enrolled

Pancreatic Adenocarcinoma Metastatic

NCT05885399 2023-06-02

The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment

5 enrolled

CNSEndocrine

Neoplasm Metastasis, Paraganglioma, Extra-Adrenal, Pheochromocytoma

NCT05726175 2023-02-13

Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer

20 enrolled

Breast

Breast Neoplasms

NCT05519202 2022-08-29

Exploratory Clinical Study of Penpulimab Combined With SOX in the Perioperative Treatment of Gastric Cancer

47 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT05485350 2022-08-03

Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)

32 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05460481 2022-07-20

Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors

29 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05244993 2022-07-12

AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer

42 enrolled

Breast

Breast Neoplasm Female

NCT04970914 2022-03-08

ALTER-C003

32 enrolled

Colorectal Neoplasms

NCT05186558 2022-03-07

Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL

54 enrolled

Lymphoid

Neoplasms by Histologic Type, Lymphoma, Large B-Cell, Diffuse

NCT05265962 2022-03-04

Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade

85 enrolled

Esophageal Squamous Cell Carcinoma

NCT04952493 2022-01-28

Anlotinib or Penpulimab in Combination With RAI for DTC

42 enrolled

Thyroid Neoplasms

NCT05137171 2021-11-30

AK105 Combined With Anlotinib in Patients With Cervical Cancer